Fundamental Analysis of NGM Biopharmaceuticals Inc - Growth / Value Index


NGM - Valuation Highlights

Valuation Analysis

   Price to Book Ratio is 0.641 indicating that it is undervalued.
   Tsr Value Index - Very Poor Score of 12.50
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -0.909 -0.841 -11.05 %
Price to Book 0.641 0.855 80.19 % 0.859
Price to Sales 28.77 5.66 154.51 %
Enterprise Value to EBITDA Multiple -0.488 -0.479 -41.42 %


NGM - Profitability Highlights

Profitability Analysis

   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -70.54 -101.68 -62.25 % -18.62
Return On Asset -60.91 -89.50 -69.14 % -16.39
Net Profit Margin -3165.68 -673.75 -129.18 % -16769.70
Operating Profit Margin -3429.09 -713.67 -137.53 % -17977.58
EBITDA Margin -3372.24 -663.42 -125.67 % -16455.76


Highlights
Market Cap128532 K
Enterprise Value72716.10 K
Price/Book TTM0.641
Outstanding Share83462.40 K
Float/ Outstanding Share34.61%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score3.00
Altman Z Score-4.04
Sloan Ratio-0.068
Peter Lynch Fair Value0


NGM - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 129.18%
   Tsr Growth Index - Very Poor Score of 18.93
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Companies' sales dropped by 59.46 % from last year
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 4417.00 K 59.46 % 71.65 %
Gross Profit 3899.00 K 96.03 % 160.65 %
EBITDA -148952.00 K 8.51 % 12.50 %
Net Profit -139828.00 K 7.09 % 3.91 %
EPS -1.69 9.95 % NA


NGM - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 95.00
   Company is Debt Free
   Net Debt zero balance-sheet with high liquidity
   Cash ratio of 7.18
   Altman Z Score of -4.04 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0 0 % 0.0093
Cash Ratio 7.18 26.53 %
Quick Ratio 0 0 % 7.79
Shareholders Equity 88.02 4.24 %
Debt to EBITDA 0 0 %


Historical Valuation Ratios of NGM Biopharmaceuticals Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of NGM Biopharmaceuticals Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of NGM Biopharmaceuticals Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of NGM Biopharmaceuticals Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)